Quick Answer
ALX ONCOLOGY HOLDINGS INC reported Total Revenue of $0.00 for fiscal year 2022.
ALX ONCOLOGY HOLDINGS INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | $0.00 | $0.00 -100.0% |
$1.18M -75.4% |
| Revenue (ASC 606) | — | — | — | $0.00 | $0.00 -100.0% |
$1.18M -75.4% |
| Net Income | -$101.69M +24.6% |
-$134.85M +16.1% |
-$160.81M -30.2% |
-$123.48M -47.9% |
-$83.46M -82.5% |
-$45.74M -137.7% |
| Diluted EPS | -$1.90 +26.4% |
-$2.58 +31.0% |
-$3.74 -23.4% |
-$3.03 -46.4% |
-$2.07 | — |
| Total Assets | $59.05M -60.0% |
$147.78M -39.1% |
$242.55M -20.9% |
$306.49M -19.4% |
$380.18M -12.8% |
$436.05M +3984.4% |
| Cash and Equivalents | $16.37M -6.8% |
$17.57M -21.6% |
$22.41M -54.1% |
$48.82M -86.6% |
$363.67M -16.2% |
$434.22M +4715.6% |
| Long-Term Debt | $4.53M -52.1% |
$9.47M -1.8% |
$9.64M +2.7% |
$9.39M | — | — |
| Stockholders Equity | $25.98M -77.1% |
$113.62M -40.1% |
$189.71M -28.0% |
$263.46M -27.4% |
$363.05M -15.5% |
$429.85M +708.5% |
| R&D Expense | $77.00M -33.8% |
$116.37M -17.9% |
$141.79M +44.1% |
$98.40M +63.5% |
$60.17M +107.8% |
$28.96M +77.6% |
| Operating Income | -$104.02M +27.0% |
-$142.47M +16.3% |
-$170.28M -33.6% |
-$127.44M -52.5% |
-$83.56M -91.4% |
-$43.66M -127.6% |
| Shares Outstanding | 54.39M +2.5% |
53.05M +6.2% |
49.95M +22.2% |
40.86M +0.7% |
40.59M +1.9% |
39.84M +1158.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2020 | $527.0K | -59.3% | -19.5% |
| Revenue (ASC 606) | June 30, 2020 | $527.0K | -59.3% | -19.5% |
| Net Income | September 30, 2025 | -$22.14M | +27.9% | +14.7% |
| Diluted EPS | September 30, 2025 | -$0.41 | +29.3% | +16.3% |
| Total Assets | September 30, 2025 | $82.72M | -55.5% | -13.2% |
| Cash and Equivalents | September 30, 2025 | $23.44M | +45.6% | +21.4% |
| Long-Term Debt | September 30, 2025 | $5.76M | -41.4% | -17.6% |
| Stockholders Equity | September 30, 2025 | $44.80M | -67.3% | -30.5% |
| R&D Expense | September 30, 2025 | $17.44M | -34.1% | -3.2% |
| Operating Income | September 30, 2025 | -$22.53M | +30.8% | +15.4% |
| Shares Outstanding | September 30, 2025 | 53.58M | +1.6% | +0.1% |
- ALX ONCOLOGY HOLDINGS INC reported Total Revenue of $0.00 for fiscal year 2022.
- ALX ONCOLOGY HOLDINGS INC reported Revenue (ASC 606) of $0.00 for fiscal year 2022.
- ALX ONCOLOGY HOLDINGS INC reported Net Income of -$101.69 million for fiscal year 2025.
- ALX ONCOLOGY HOLDINGS INC showed an increase of +24.6% in Net Income compared to the prior fiscal year.
- ALX ONCOLOGY HOLDINGS INC reported Diluted EPS of $1.90 per share (loss) for fiscal year 2025.
- ALX ONCOLOGY HOLDINGS INC showed an increase of +26.4% in Diluted EPS compared to the prior fiscal year.
- ALX ONCOLOGY HOLDINGS INC reported Total Assets of $59.05 million for fiscal year 2025.
- ALX ONCOLOGY HOLDINGS INC showed a decrease of -60.0% in Total Assets compared to the prior fiscal year.
- ALX ONCOLOGY HOLDINGS INC reported Cash and Equivalents of $16.37 million for fiscal year 2025.
- ALX ONCOLOGY HOLDINGS INC showed a decrease of -6.8% in Cash and Equivalents compared to the prior fiscal year.
- ALX ONCOLOGY HOLDINGS INC reported Long-Term Debt of $4.53 million for fiscal year 2025.
- ALX ONCOLOGY HOLDINGS INC showed a decrease of -52.1% in Long-Term Debt compared to the prior fiscal year.
- ALX ONCOLOGY HOLDINGS INC reported Stockholders Equity of $25.98 million for fiscal year 2025.
- ALX ONCOLOGY HOLDINGS INC showed a decrease of -77.1% in Stockholders Equity compared to the prior fiscal year.
- ALX ONCOLOGY HOLDINGS INC reported R&D Expense of $77.00 million for fiscal year 2025.
- ALX ONCOLOGY HOLDINGS INC showed a decrease of -33.8% in R&D Expense compared to the prior fiscal year.
- ALX ONCOLOGY HOLDINGS INC reported Operating Income of -$104.02 million for fiscal year 2025.
- ALX ONCOLOGY HOLDINGS INC showed an increase of +27.0% in Operating Income compared to the prior fiscal year.
- ALX ONCOLOGY HOLDINGS INC reported Shares Outstanding of 54.39 million shares for fiscal year 2025.
- ALX ONCOLOGY HOLDINGS INC showed an increase of +2.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: